Bayer files prostate cancer drug darolutamide with EU regulatorsAfter filings in the US and Japan, Bayer has submitted data to European regulators for its prostate cancer Share XBayer files prostate cancer drug darolutamide with EU regulatorshttps://pharmaphorum.com/news/bayer-files-prostate-cancer-drug-darolutamide-with-eu-regulators/
Bayer files prostate cancer drug darolutamide in JapanBayer has filed its prostate cancer drug darolutamide with Japanese regulators, in an attempt to ratchet up the Share XBayer files prostate cancer drug darolutamide in Japanhttps://pharmaphorum.com/news/bayer-files-prostate-cancer-drug-darolutamide-in-japan/
Bayer completes US filing for prostate cancer drug darolutamideBayer has completed its rolling marketing application for prostate cancer drug darolutamide in the US, setting up possible Share XBayer completes US filing for prostate cancer drug darolutamidehttps://pharmaphorum.com/news/bayer-completes-us-filing-for-prostate-cancer-drug-darolutamide/
Trial could unlock new prostate cancer sales for Pfizer/Astellas’ XtandiPfizer and Astellas’ Xtandi has shown it is effective in men with prostate cancer that has spread but Share XTrial could unlock new prostate cancer sales for Pfizer/Astellas’ Xtandihttps://pharmaphorum.com/news/trial-prostate-cancer-pfizer-astellas-xtandi/
Bayer/Orion showcase results from prostate cancer challengerBayer and development partner Orion have released detailed results from the trial that will form the backbone of Share XBayer/Orion showcase results from prostate cancer challengerhttps://pharmaphorum.com/news/bayer-orion-showcase-results-from-prostate-cancer-challenger/
J&J shares fall after court refuses to block Zytiga genericsJohnson & Johnson’s share price took a beating this week after the US appeals court declined its bid Share XJ&J shares fall after court refuses to block Zytiga genericshttps://pharmaphorum.com/news/jj-shares-fall-after-court-refuses-to-block-zytiga-generics/
Bayer plans filings for prostate cancer drug darolutamideBayer is planning regulatory filings of darolutamide in prostate cancer following phase III trial results showing it helped Share XBayer plans filings for prostate cancer drug darolutamidehttps://pharmaphorum.com/news/bayer-plans-filings-for-prostate-cancer-drug-darolutamide/
Clovis hopes to get ahead of rivals in prostate cancer with RubracaClovis’ PARP inhibitor drug Rubraca is showing promise in prostate cancer, according to data released at this year’s Share XClovis hopes to get ahead of rivals in prostate cancer with Rubracahttps://pharmaphorum.com/news/clovis-hopes-to-get-ahead-of-rivals-in-prostate-cancer-with-rubraca/
FDA says Clovis’ Rubraca could be prostate cancer breakthroughClovis Oncology’s Rubraca (rucaparib) has been designated as a Breakthrough Therapy by the FDA in prostate cancer, paving Share XFDA says Clovis’ Rubraca could be prostate cancer breakthroughhttps://pharmaphorum.com/news/fda-says-clovis-rubraca-could-be-prostate-cancer-breakthrough/
